摘要
1983—1987年,共收治非何杰金淋巴瘤(NHL)化疗有/无放疗276例(单纯化疗95例,化疗加放疗181例)。按国际工作分类,低、中、高度恶性各占4.7％、47％、42.8％,其它5.5％。原发于结内73.2％。本组病例偏晚,ⅢⅣ期占54.4％;B组占全部之1/3。化疗方案以COPP、CHOP、MOPP为主,疗后CR118例(42.8％)、PR93例(33.7％)、CR+PR率76.5％;疗后1、3、5年生存率各为55.1％、29.3％、19.2％。经分析在病理类型、临床分期、A组B组、近期疗效与预后关系密切,治疗在ⅢⅣ期则以足量化+放疗效果较佳。本组毒性反应不严重,无毒性死亡病例。
From 1983 to June 1987, 276 cases of non-Hodgkin's lymphomas (NHL) treated by chemotherapy (CT) and/or Radiotherapy (RT) in our hospital. The ratio of male to female was 3.1: 1. The low, intermediate and high grade malignant lymphoma were 4.7％, 47％, 42.8％ respectively The primary location in lymph nodes were 202cases (73.2％) , out of the lymph nodes were 26.8％. There were 34, 92, 71 and 79 cases in stage Ⅰ, Ⅱ, Ⅲ and Ⅳ respectively, stage Ⅲ to Ⅳ occupy 54,4％, There were 98 cases at B group. On treatment, only combined CT 97 cases, CT+RT 179 cases, the regime of CT were COPP (CTX. VCR. PCZ PDN) CHOP (CTX ADM VCR PDN) MOPP (HN2 VCR PCZ PDN). After treatment, the CR+PR rate were reached to 76.5％ (CR 42.8％ PR 33.7％) and the one year survival of the whole group was 152 cases (55.1％), two years 106 cases (38.4％) , three years 54 cases (29.3％), four years 23 cases (17.8％) five years 10 cases (19.2％), Among of 276 cases, the prognosis of NHL were related to the type of pathology, the stage of clinic, the A or B groups, the rate of CR+PR etc.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
1991年第3期163-167,共5页
Cancer Research on Prevention and Treatment
